期刊文献+

肾移植受者血清IL-10测定的临床意义 被引量:1

Evaluation of IL-10 in Renal Allograft Recipients
下载PDF
导出
摘要 目的观察肾移植受者术后肾功能稳定、发生排异反应、感染、慢性移植肾肾病(CAN)时血清白细胞介素-10(IL-10)的水平;检测肾功能稳定者肾移植术后不同时间、环孢菌素A(CsA)剂量、排异次数时血清IL-10水平,以探讨IL-10在肾移植受者门诊随访中的意义。方法采用双抗体夹心酶联免疫吸附法,随机对127例门诊肾移植术后随访者血清IL-10水平进行检测。以20例健康志愿者作为对照组。结果肾功能稳定组患者的血清IL-10水平明显高于术后排异组、CAN组和对照组,相比较均有显著统计学意义(P<0.05);肾功能稳定组中CsA用量每千克体质量2 mg组的血清IL-10水平明显高于4 mg组,相比有统计学意义(P<0.05);该组中移植术后无排异者的血清IL-10水平明显高于1次排异和多次排异者,相比均有统计学意义(P<0.05)。结论血清IL-10水平可部分反映移植患者的免疫状态,对肾移植受者门诊随访有一定的参考价值。 Objective To study the level of serum IL-10 in renal allgraft recipients with stable renal function,acute rejection, infection and chronic allgraft nephropathy (CAN) , and to study the level of serum IL-10 in stable renal function recipients with different postoperative time, different dosage of CsA, different rejective frequency in order to find out the value of IL-10 in the follow-up of out-patients. Methods IL-10 were detected randomly by ELISA technique in 127 renal allgraft recipients during the follow-up, and 20 healthy volunteers were enrolled as controls.Results Level of serum IL-10 in stable renal function group was significantly higher than that in rejection group,CAN group and control group(P 〈0.05). In stable renal function recipients, serum IL-10 level was much higher in patients with 2 mg/kg CsA than that in patients with 4 mg/kg CsA (P 〈 0.05), and serum IL-10 level was obviously higher in patients without rejection than that in patients with at least one rejection ( P 〈 0.05 ). Conclusion The level of serum IL-10 can partially reflect the immune state of renal allgraft recipients, which have some reference value in the follow-up of out-patients.
出处 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2006年第6期685-688,共4页 Journal of Shanghai Jiao tong University:Medical Science
关键词 肾移植 白细胞介素-10 免疫耐受 肾功能 renal transplantation interleukin-10 immunological tolerance renal function
  • 相关文献

参考文献11

  • 1Fiorentino DF,Bond MW,Mosmann TR,et al.Two types of mouse T-helper cell.IV.Th2 clones secrete a factor that inhibits cytokine production by Th1 clones[J].J Exp Med,1989,170(6):2081-2095.
  • 2Peter N,Sterger J,Zheng XX,et al.Manipulation of cytokine networks in transplantation[J].Transplantation,1997,63(4):489-494.
  • 3Stephane.V,Eric.Y,Ettore.B,et al.Antigen-induced regulatory T cells[J].Blood,2004,104(1):26-33.
  • 4Levings MK,Sangregorio R,Roncarolo MG.Human CD25^+CD4^+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function[J].J Exp Med,2001,193(7):1295-1302.
  • 5Kingsley CI,Karim M,Bushell AR,et al.CD25^+CD4^+ regulatory T cells prevent graft rejection:CTLA-4-and IL-10-dependent immunoregulation of alloresponses[J].J Immunol,2002,168(3):1080-1088.
  • 6Zuo Z,Wang C,Carpenter D,et al.Prolongation of allograft survival with viral IL-10 transfection in a highly histoincompatible model of rat heart allograft rejection[J].Transplantation,2001,71(5):686-691.
  • 7Hara M,Kingsley CI,Niimi M,et al.IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo[J].J Immunol,2001,166(6):3789-3796.
  • 8Calne R."Almost tolerance" in the clinic[J].Transplant Proce,1998,30(7):3846-3848.
  • 9Olszyna DP,Pajkrt D,Lauw FN,et al.Interleukin 10 Inhibits the Release of CC Chemokines during Human Endotoxemia[J].J Infect Dis,2000,181(2):613-620.
  • 10Abarmowicz D,Manas D,Lao M,et al.Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients:a randominzed,controlled study[J].transplantation,2002,74(12):1725-1734.

同被引文献19

  • 1Arce J,Rosales A,Caffaratti J,et al.Renal retransplantation: risk factors and results.Actas Urol Esp.2011: 35(1):44-50.
  • 2Steinmetz OM,Stahl RA,Panzer U.Chemokines and B cells in renal inflammation and allograft rejection.Front Biosci.2009: 1:13-22.
  • 3Badiou S, Cristol JP, Mourad G.Dyslipidemia following kidney transplantation: diagnosis and treatment.Curr Diab Rep.2009: 9(4):305-311.
  • 4Calmus Y, Pageaux G.Renal failure following liver transplantation Presse Med.2009: 38(9):1314-1318.
  • 5Marcen R.Immunosuppressive drugs in kidney transplantation: impact on patient survival,and incidence of cardiovascular disease,malignancy and infection.Drugs.2009:69(16):2227-2243.
  • 6Knoll G.Trends in kidney transplantation over the past decade. Drugs.2008; 68(Suppl 1):3-10.
  • 7Vicari-Christensen M,Repper S,Basile S,et aI.Tacrolimus: review of pharmacokinetics,pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence.Prog Transplant. 2009: 19(3):277-284.
  • 8Halloran PF.T cell-mediated rejection of kidney transplants: a personal viewpoint.Am J Transplant.2010; 10(5): 1126-1134.
  • 9Fischereder M, Schroppel B.The role of chemokines in acute renal allograft rejection and chronic allograft injury.Front Biosci. 2009: 14:1807-1814.
  • 10Montague T, Murphy B.Lipid management in chronic kidney disease, hemodialysis, and transplantation.Endocrinol Metab Clin North Am.2009: 38(1):223-234.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部